Polimorfismo dos genes ABO, Lewis e Secretor correlacionados com o câncer de mama
Carregando...
Data
2007-02-14
Autores
Gradella, Débora Barreto Teresa [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
A expressão de antígenos ABH e Lewis tem sido associada com o desenvolvimento e prognóstico do câncer, diferenciação tumoral e metástase. Considerando que o carcinoma ductal invasivo (CADI) de mama apresenta múltiplas alterações, o objetivo deste estudo foi avaliar se o polimorfismo dos genes ABO, Lewis e Secretor, bem como a fenotipagem ABO podem estar associados ao câncer de mama e com parâmetros anatomoclínicos do tumor. Foram avaliadas 76 mulheres portadoras de CADI e 78 mulheres doadoras de sangue para a fenotipagem/genotipagem ABO e genotipagem Lewis e Secretor. Fenotipagem foi realizada por método de hemaglutinação, a genotipagem ABO por PCR seguida de restrição enzimática e a genotipagem dos grupos Lewis e Secretor por PCR alelo específico (PCR-AE). A genotipagem foi realizada considerando o polimorfismo dos genes em um único nucleotídeo, sendo que para o gene Lewis nas posições 59, 1067, 202 e 314, para o gene Secretor na posição 428 e para o gene ABO nas posições 261 (alelo O1), 526 (alelos O2 e B) e 703 (alelo B). Os genótipos Lewis foram classificados em Lewis positivo (tipo selvagem ou com duas/três mutações) e Lewis negativo (duas a quatro mutações). O genótipo secretor foi classificado em Secretor (selvagem ou com a mutação em heterozigose) e Não-secretor (homozigoto mutante). Nenhuma associação foi encontrada entre as pacientes com câncer de mama e o fenótipo (P=0,9323) e genótipo (P=0,9356) ABO. Mulheres com genótipo Lewis negativo foram associadas com CADI (P=0,0126), mas não foram associadas com os parâmetros anatomoclínicos (tamanho tumor, estadiamento TNM e metástase em linfonodos axilares). Genótipo Não-secretor foi associado com metástase em linfonodos axilares (P=0,0149). Em conclusão, os genótipos Lewis e Secretor podem ser úteis para predizer, respectivamente suscetibilidade e metástase em linfonodos axilares.
ABH and Lewis antigens expression have been associated with cancer development, prognosis, tumor differentiation and metastasis. Considering that invasive ductal breast carcinoma (IDC) present multiple molecular alterations, the aim of the present study was evaluated if the polymorphism of ABO, Lewis and secretor genes, as well as ABO phenotyping could be associated to breast cancer and anatomoclinical parameters of the tumor. In 76 women with IDC and 78 health women blood donors, ABO phenotyping/genotyping, Lewis and Secretor genotyping were evaluated. Phenotyping was performed by hemmaglutination method and genotyping by Polymerase Chain Reaction with Sequence-Specific Primers (PCR-SSP). ABO, Lewis and Secretor were classified by individual single nucleotide polymorphism (SNP) at sites 59, 1067, 202 and 314 of the Lewis gene, 428 of the Secretor gene and 261 (O1 allele), 526 (O2 and B allele) and 703 (B allele). Lewis genotype was classified in Lewis positive (wild-type or two/three SNPs) or Lewis negative (two to four different SNPs). The Secretor genotype was classified in Secretor (wild type or SNP in heterozygoses) and Non-secretor (SNP in homozygoses). No association was found between patients with breast cancer and ABO antigen expression (P=0.9323) and genotypes (P=0.9356). Lewis negative was associated with IDC (P=0.0126), but were not associated with anatomoclinical parameters (tumor size, TNM staging and axillary lymph nodes metastasis). Non-secretor genotype was associated with axilary lymph nodes metastasis (P=0.0149). In conclusion, the Lewis and Secretor genotyping could be useful to predict, respectively, of breast cancer susceptibility and axillary lymph nodes metastasis.
ABH and Lewis antigens expression have been associated with cancer development, prognosis, tumor differentiation and metastasis. Considering that invasive ductal breast carcinoma (IDC) present multiple molecular alterations, the aim of the present study was evaluated if the polymorphism of ABO, Lewis and secretor genes, as well as ABO phenotyping could be associated to breast cancer and anatomoclinical parameters of the tumor. In 76 women with IDC and 78 health women blood donors, ABO phenotyping/genotyping, Lewis and Secretor genotyping were evaluated. Phenotyping was performed by hemmaglutination method and genotyping by Polymerase Chain Reaction with Sequence-Specific Primers (PCR-SSP). ABO, Lewis and Secretor were classified by individual single nucleotide polymorphism (SNP) at sites 59, 1067, 202 and 314 of the Lewis gene, 428 of the Secretor gene and 261 (O1 allele), 526 (O2 and B allele) and 703 (B allele). Lewis genotype was classified in Lewis positive (wild-type or two/three SNPs) or Lewis negative (two to four different SNPs). The Secretor genotype was classified in Secretor (wild type or SNP in heterozygoses) and Non-secretor (SNP in homozygoses). No association was found between patients with breast cancer and ABO antigen expression (P=0.9323) and genotypes (P=0.9356). Lewis negative was associated with IDC (P=0.0126), but were not associated with anatomoclinical parameters (tumor size, TNM staging and axillary lymph nodes metastasis). Non-secretor genotype was associated with axilary lymph nodes metastasis (P=0.0149). In conclusion, the Lewis and Secretor genotyping could be useful to predict, respectively, of breast cancer susceptibility and axillary lymph nodes metastasis.
Descrição
Palavras-chave
Gene ABO, Gene Lewis, Gene Secretor, Câncer de mamas, Polimorfismo (Genetica), Breast cancer
Como citar
GRADELLA, Débora Barreto Teresa. Polimorfismo dos genes ABO, Lewis e Secretor correlacionados com o câncer de mama. 2007. 119 f. Tese (doutorado) - Universidade Estadual Paulista, Faculdade de Ciências Farmacêuticas, 2007.